曾亚琳, 陈笑艳, 张逸凡, 钟大放. 液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康J. 药学学报, 2004, 39(2): 132-135.
引用本文: 曾亚琳, 陈笑艳, 张逸凡, 钟大放. 液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康J. 药学学报, 2004, 39(2): 132-135.
ZENG Ya-lin, CHEN Xiao-yan, ZHANG Yi-fan, ZHONG Da-fang. Determination of lornoxicam in human plasma by LC/MS/MSJ. Acta Pharmaceutica Sinica, 2004, 39(2): 132-135.
Citation: ZENG Ya-lin, CHEN Xiao-yan, ZHANG Yi-fan, ZHONG Da-fang. Determination of lornoxicam in human plasma by LC/MS/MSJ. Acta Pharmaceutica Sinica, 2004, 39(2): 132-135.

液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康液相色谱-质谱-质谱联用法测定人血浆中氯诺昔康

Determination of lornoxicam in human plasma by LC/MS/MS

  • 摘要: 目的建立测定人血浆中氯诺昔康的液相色谱-质谱-质谱联用法,并用于中国受试者口服氯诺昔康的体内药代动力学研究。方法血浆样品经液-液萃取后,以甲醇-水-甲酸(80∶20∶0.5)为流动相,吡罗昔康为内标,采用Zorbax XDB-C8柱分离,通过液相色谱串联质谱,以选择反应监测(SRM)方式进行检测。定量分析离子反应分别为m/z 372→121(氯诺昔康)和m/z 332→121(吡罗昔康)。结果线性范围为2.0~1 600 μg·L-1,定量下限为2.0 μg·L-1。18名受试者po氯诺昔康8 mg后主要药动学参数t1/2为(4.7±1.1) h,AUC0-∞为(5.5±2.4) mg·h·L-1。而另一名受试者t1/2为105 h,AUC0-∞为189.5 mg·h·L-1。结论该法灵敏度高,线性范围宽,操作简便、快速,适用于临床药代动力学研究。

     

    Abstract: AimTo develop a sensitive and specific LC/MS/MS method for determination of lornoxicam in human plasma and investigate pharmacokinetics of single dose of lornoxicam in healthy Chinese volunteers. MethodsLornoxicam and the internal standard piroxicam were extracted from plasma using liquid-liquid extraction, then separated on a Zorbax XDB-C8 column. The mobile phase consisted of methanol-water-formic acid (80∶20∶0.5) at a flow-rate of 0.7 mL·min-1. A Finnigan TSQ tandem mass spectrometer equipped with atmospheric pressure chemical ionization source was used as detector and operated in the positive ion mode. Selected reaction monitoring (SRM) using the precursor → product ion combinations of m/z 372→121 and m/z 332→121 was used to quantify lornoxicam and internal standard, respectively. ResultsThe linear calibration curves were obtained in the concentration range of 2.0-1 600 μg·L-1. The limit of quantitation was 2.0 μg·L-1. The method was successfully used in the pharmacokinetic study for lornoxicam. The main parameters obtained after an oral dose of 8 mg lornoxicam to 18 Chinese male volunteers were as follows: the value of t1/2 was (4.7±1.1) h, AUC0-∞ was found to be (5.5±2.4) mg·h·L-1. However, t1/2 of 105 h and AUC0-∞ of 189.5 mg·h·L-1 were obtained for another volunteer. ConclusionThe method is proved to be suitable for clinical investigation of lornoxicam pharmacokinetics, which offers advantages of specificity, speed, and higher sensitivity over the previously reported methods.

     

/

返回文章
返回